Short Communication
Abdalla Abotaleb
Abstract
At low middle-income countries like Egypt with prevalence of (HCV) which represent from 5 to 7% of total population. Hepatocellular carcinoma is one of major complications of HCV infection At Africa for example Egypt is accounting for approximately half of the data related to HCC. Over the last two decades, a substantial increase (from 4.0% to 7.2%) in the proportion of chronic liver disease Egyptian patients with HCC was observed. This percentage raise some questions like • How government afford innovative products for high number of patients? • Are these innovative products worthy for reimbursement? • What is the impact on budget? The main objective behind conducting this study was to conduct an economic evaluation of Sorafenib for the treatment of hepatocellular carcinoma in the Egyptian patients, compared to standard of care perspective of the National Fund over a time horizon of 4 years. To maximize health gain for the patients while ensuring the most efficient use of the finite resources available to the Egyptian Ministry of Health. Methods: A cost-effectiveness analysis from the payer perspective using Markov chain simulation model which is hypothetical cohort model to conforms to real practice of management of advanced HCC in Egypt.